1. Clinical & Scientific Overview
Other Commonly Used Hormonal Medicines (Deflazacort, Dexamethasone, Fludrocortisone, & Gynaecological Progestogens) (TIP-MED-000452, Reference Code [6.6]) is classified under
Endocrine & Hormonal Medicines as a Systemic Glucocorticoids (Deflazacort, Dexamethasone), Mineralocorticoid (Fludrocortisone), and Oral Progestogens (Norethisterone, Medroxyprogesterone).
Within the Indian regulatory and compendial framework, it is governed under Schedule G / Schedule H (Medical Supervision Mandatory).
Representative Indian Formulations (for identification only): Deflazacort: Defcort (Macleods), Dezacor, Orthocort (1 mg, 6 mg, 12 mg, 24 mg, 30 mg). Dexamethasone: Dexona (Zydus—0.5 mg, 4 mg), Decdan. | Strengths: Deflazacort Tablets: 6 mg, 12 mg, 24 mg, 30 mg; Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg & Injection 4 mg/mL; Fludrocortisone Tablets: 0.1 mg (100 mcg); Norethisterone Tablets: 5 mg, 10 mg CR;
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Systemic Glucocorticoids (Deflazacort, Dexamethasone), Mineralocorticoid (Fludrocortisone), and Oral Progestogens (Norethisterone, Medroxyprogesterone)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in • Deflazacort: Oxazoline derivative of prednisolone (6 mg Deflazacort = 5 mg Prednisolone) used in rheumatoid arthritis, asthma, nephrotic syndrome, and Duchenne muscular dystrophy (slightly lower diabetogenic and bone loss profile at equipotent doses, though all steroid precautions still apply).
4. Therapeutic Indications & Evidence-Supported Uses
- • Deflazacort: Oxazoline derivative of prednisolone (6 mg Deflazacort = 5 mg Prednisolone) used in rheumatoid arthritis, asthma, nephrotic syndrome, and Duchenne muscular dystrophy (slightly lower diabetogenic and bone loss profile at equipotent doses, though all steroid precautions still apply)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Deflazacort: 6 mg–30 mg OD after breakfast. Dexamethasone: 0.5 mg–8 mg/day after breakfast. Fludrocortisone: 50 mcg–200 mcg (0.5 to 2 tablets of 0.1 mg) once daily in the morning. Norethisterone: 5 mg twice or three times daily for 5–21 days per gynaecologist schedule. (Duration: Strictly per indication; taper Deflazacort/Dexamethasone if used >2 weeks. For Norethisterone/Medroxyprogesterone in AUB, complete the exact 5-, 10-, or 21-day cycle (withdrawal bleeding normally occu.)
Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified) | Food & Meal Timing: Take with or after meals (especially breakfast for corticosteroids) to prevent gastric irritation. | Best Time of Day: Corticosteroids & Fludrocortisone: Once daily in the morning after breakfast. Progestogens (Norethisterone/Medroxyprogesterone): Divided 2–3 times daily or once daily at the same c.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal: Monitor fluid retention and BP with Fludrocortisone and steroids in CKD. Hepatic: Oral progestogens (Norethisterone/Meprate) are contraindicated in severe hepatic dysfunction or active jaundice.
Renal: Monitor fluid retention and BP with Fludrocortisone and steroids in CKD. Hepatic: Oral progestogens (Norethisterone/Meprate) are contraindicated in severe hepatic dysfunction or active jaundice.
Renal: Monitor fluid retention and BP with Fludrocortisone and steroids in CKD. Hepatic: Oral progestogens (Norethisterone/Meprate) are contraindicated in severe hepatic dysfunction or active jaundice.
7. Contraindications, Precautions & High-Risk Warnings
- Glucocorticoids: Same precautions as Prednisolone (hyperglycaemia, GI ulceration with NSAIDs, osteoporosis, infection, HPA suppression—note that Dexamethasone has a 36–54 hour biological half-life and strongly suppresses the HPA axis!)
- Fludrocortisone: Contraindicated in congestive heart failure and uncontrolled severe hypertension
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Deflazacort/Dexamethasone: Hyperglycaemia, insomnia, dyspepsia, Cushingoid changes
- Fludrocortisone: Sodium/water retention, ankle oedema, supine hypertension, hypokalaemia
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP3A4 inducers (rifampicin, phenytoin, carbamazepine) accelerate clearance of dexamethasone, deflazacort, and progestogens
- NSAIDs + glucocorticoids cause peptic ulceration
- Fludrocortisone + loop/thiazide diuretics cause profound hypokalaemia
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- • Steroid Potency Equivalence Check: Ensure patients and staff know that 6 mg Deflazacort = 5 mg Prednisolone = 4 mg Methylprednisolone = 0
- 75 mg Dexamethasone —never confuse mg strengths across steroids! • Floricot Storage Alert: Some Fludrocortisone brands require refrigerator storage (2°C–8°C) or cool storage ( • Primolut-N / Meprate C
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Deflazacort Tablets: 6 mg, 12 mg, 24 mg, 30 mg; Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg & Injection 4 mg/mL; Fludrocortisone Tablets: 0.1 mg (100 mcg); Norethisterone Tablets: 5 mg, 10 mg CR;). Missed-Dose Rule: Take as soon as remembered on the same day. For Norethisterone in Abnormal Uterine Bleeding, missing even 1–2 doses causes immediate breakthrough vaginal bleeding—maintain strict 8- or 12-hourly clock.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)